Case #56 – The dawn of Pharmaco-Genetics for AMD

The dawn of Pharmaco-Genetics for AMD – Page 57 of 57

Additional ReadingsAlgvere PV. Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmology. 2006 Feb;84(1):4-15. Taylor HR, Muñoz B. West S. Bressler NM, Bressler SB. Rosenthal FS: Visible light and risk of age-related macular degeneration. Dana Center for Preventive Ophthalmology, Wilmer Institute, Johns Hopkins University, Baltimore, Maryland. Trans Am Ophthalmology 199o:

The dawn of Pharmaco-Genetics for AMD – Page 57 of 572023-01-31T21:30:10+00:00

The dawn of Pharmaco-Genetics for AMD – Page 56 of 57

References• Carl C. Awh, Anne-Marie Lane, Steven Hawken, Brent Zanke, Ivana K. Kim, CFH and ARMS2 Genetic Polymorphisms Predict Response to Antioxidants and Zinc in Patients with Age-related Macular Degeneration, Ophthalmology, Available online 21 August 2013

The dawn of Pharmaco-Genetics for AMD – Page 56 of 572023-01-31T21:30:10+00:00

The dawn of Pharmaco-Genetics for AMD – Page 54 of 57

Jerome Sherman, OD, FAAO Jerome Sherman, O.D., is perhaps optometry's most prolific writer, publishing over 650 clinical articles, research manuscripts, book chapters and two CDs. He is senior author of three books that were published in 2007, and has delivered over three thousand lectures both nationally and internationally. He has served as a

The dawn of Pharmaco-Genetics for AMD – Page 54 of 572023-01-31T21:30:11+00:00

The dawn of Pharmaco-Genetics for AMD – Page 53 of 57

Comments and ConclusionsAs Americans live longer, AMD is reaching epidemic proportions.With improved imaging technologies, AMD appears to be present in a younger population than previously believed.MSI is a novel imaging procedure which is ideal in detecting early melanin changes in AMD as well as in myriad other disorders.SD OCT and AF are also quite valuable

The dawn of Pharmaco-Genetics for AMD – Page 53 of 572023-01-31T21:30:11+00:00

The dawn of Pharmaco-Genetics for AMD – Page 51 of 57

BluTechTM Combats the Evolving Threat of Indoor Lighting The benefits of the novel BluTech lenses have recently received the attention of the ophthalmic community. Fluorescent and LED lights are replacing the incandescent bulb with a spectral curve peaking early in the blue wavelengths, dropping off, and providing moderate light in the middle of the

The dawn of Pharmaco-Genetics for AMD – Page 51 of 572023-01-31T21:30:11+00:00

The dawn of Pharmaco-Genetics for AMD – Page 50 of 57

Macular Carotenoid Strength  Based upon impressive research results, many clinicians recommend carotenoids to their patients with AMD. At the Eye Institute, MacuHealth is our choice and here are some reasons: As it turns out, these pigments are arranged in our macula in this bulls eye type of pattern for a reason, which seems to

The dawn of Pharmaco-Genetics for AMD – Page 50 of 572023-01-31T21:30:11+00:00

The dawn of Pharmaco-Genetics for AMD – Page 49 of 57

Case 6: Annidis MSI Red2 OD Here Is another relatively young patient with possible early AMD. Modifications in lifestyle, genetic testing and supplements all are reasonable considerations.

The dawn of Pharmaco-Genetics for AMD – Page 49 of 572023-01-31T21:30:12+00:00

The dawn of Pharmaco-Genetics for AMD – Page 48 of 57

Case 6: Annidis MSI OD The following images reveal early RPE epitheliopathy in a 44-year old Caucasian, very heavy smoker — quit 1 year ago, with light irides. a poor self-reported diet and no family history of AMD. She has no myopia or risk factors for other retinal disease or dystrophy.*Contributed by Dorothy Hitchmoth,

The dawn of Pharmaco-Genetics for AMD – Page 48 of 572023-01-31T21:30:12+00:00